drugset / Trial / NCT00831103

A Phase 2b Trial of EPB-348 for the Treatment of Herpes Zoster

NCT00831103

Phase 2 Completed 373 enrolled Epiphany Biosciences
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine the pharmacokinetics and dosage of EPB-348 that best balances safety and efficacy among adult immunocompetent patients with an acute episode of herpes zoster.

Timeline

Start
2007-11
Primary completion
2009-06
Completion
2009-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Valacyclovir Unknown 1000 mg
Subject Valomaciclovir Small molecule 1000 mg
Subject Valomaciclovir Small molecule 2000 mg
Subject Valomaciclovir Small molecule 3000 mg

Indications